BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, Vellucci V, Hernandez D, McPhee F. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother 2016;71:3495-505. [PMID: 27605597 DOI: 10.1093/jac/dkw336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses 2017;9:E212. [PMID: 28783119 DOI: 10.3390/v9080212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
2 Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep 2018;8:8988. [PMID: 29895871 DOI: 10.1038/s41598-018-26862-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
3 McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology 2019;69:2349-63. [PMID: 30693573 DOI: 10.1002/hep.30527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Lu J, Feng Y, Chen L, Zeng Z, Liu X, Cai W, Wang H, Guo X, Zhou H, Tao W, Xie Q. Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Front Microbiol 2019;10:535. [PMID: 30941111 DOI: 10.3389/fmicb.2019.00535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
6 Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Dig Liver Dis 2017;49:731-41. [PMID: 28456519 DOI: 10.1016/j.dld.2017.03.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
7 Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Youn J, Wang CY, Llewellyn J, Matsuda T, Gaggar A, Mo H, Dvory-Sobol H, Crans G, Chuang WL, Chen PJ, Enomoto N. Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. Hepatol Res 2020;50:1109-17. [PMID: 32614468 DOI: 10.1111/hepr.13546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother 2017;61:e02558-16. [PMID: 28193664 DOI: 10.1128/AAC.02558-16] [Cited by in Crossref: 89] [Cited by in F6Publishing: 38] [Article Influence: 17.8] [Reference Citation Analysis]
9 Asante-Appiah E, Liu R, Curry S, McMonagle P, Agrawal S, Carr D, Rokosz L, Lahser F, Bystol K, Chase R, Black S, Ferrari E, Ingravallo P, Tong L, Yu W, Kozlowski J. In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrob Agents Chemother 2018;62:e01280-18. [PMID: 30150466 DOI: 10.1128/AAC.01280-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Gamal N, Gitto S, Andreone P. Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview. J Clin Transl Hepatol 2016;4:336-44. [PMID: 28097103 DOI: 10.14218/JCTH.2016.00038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Tsai WL, Wang CF, Cheng JS, Chen WC, Bair MJ, Lo CC. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. PLoS One 2020;15:e0227424. [PMID: 31923251 DOI: 10.1371/journal.pone.0227424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ma CD, Imamura M, Talley DC, Rolt A, Xu X, Wang AQ, Le D, Uchida T, Osawa M, Teraoka Y, Li K, Hu X, Park SB, Chalasani N, Irvin PH, Dulcey AE, Southall N, Marugan JJ, Hu Z, Chayama K, Frankowski KJ, Liang TJ. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. Nat Microbiol 2020;5:1532-41. [PMID: 32868923 DOI: 10.1038/s41564-020-0781-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Asante-Appiah E, Ingravallo P, McMonagle P, Bystol K, Xia E, Curry S, Qiu P, Black S, Chase R, Liu R, Lahser F. Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in HCV GT2. Antimicrob Agents Chemother 2019:AAC. [PMID: 31527040 DOI: 10.1128/AAC.01269-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]